Antigen News and Research

RSS

Defects in carbon nanotubes stimulate body's natural immune response: Study

Yale University engineers have found that the defects in carbon nanotubes cause T cell antigens to cluster in the blood and stimulate the body's natural immune response.

21 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.

20 Apr 2010

Screening rates for skin cancer low among middle-aged and older Caucasian adults: CINJ study

Among people over 50, those who did not finish high school or have not recently had common cancer screenings such as a mammogram, prostate-specific antigen test or colorectal cancer screening, are also less likely to be screened for skin cancer.

20 Apr 2010

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

LifeSpan BioSciences, Inc., a leading provider of antibodies for thousands of researchers worldwide, has increased the number of validated IHC-plus™ antibodies available in its catalog to more than 3,500. With this increase, LifeSpan is well on its way to building the world's largest catalog of well characterized, IHC-validated reagent antibodies. Overall, LifeSpan has a catalog of more than 82,000 antibodies.

20 Apr 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute®-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting.

20 Apr 2010

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

19 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Investment report on Generex Biotechnology from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

19 Apr 2010

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

NSF Faculty Early Career Development Award for Zhihao Zhuang

Zhihao Zhuang, assistant professor in the Department of Chemistry and Biochemistry at the University of Delaware, has won the National Science Foundation Faculty Early Career Development Award.

17 Apr 2010

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex arrays from Protein Biotechnologies.

17 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has entered into a Cooperative Research and Development Agreement with the Naval Medical Research Center. NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.

16 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Molecular biologist Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network - American Association of Cancer Research Career Development Award in memory of Skip Viragh.

15 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

Antigen News and Research

Defects in carbon nanotubes stimulate body's natural immune response: Study

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Screening rates for skin cancer low among middle-aged and older Caucasian adults: CINJ study

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Investment report on Generex Biotechnology from MicroStockProfit.com

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

NSF Faculty Early Career Development Award for Zhihao Zhuang

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Serametrix announces commercial launch of serum test for measuring serum antibodies

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Targeted therapy MDV3100 is effective for patients with CRPC: Study

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics